CARLSBAD, Calif.--(BUSINESS WIRE)--GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the Canaccord Genuity 34th Annual Growth Conference to be held at the InterContinental Boston Hotel in Boston, MA on Wednesday, August 13, 2014. The presentation will be delivered by Scott Mendel, Chief Financial Officer and is scheduled to begin at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time). The presentation will be made available at http://ir.genmarkdx.com/.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark’s proprietary eSensor® detection technology, GenMark’s eSensor® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory Viral Panel, Thrombophilia Risk Test, and Warfarin Sensitivity Test. A number of other tests, including HCV Genotyping, 2C19 Genotyping, and 3A4/3A5 Genotyping are available for research use only. For more information, visit www.genmarkdx.com.